# COACTION Trial - COmbination Androgen bloCkade in inTermediate to hIgh-risk prOstate caNcer

> **NCT06627530** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Brazilian Clinical Research Institute** · enrollment: 144 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Darolutamide Oral Tablet
- **DRUG:** leuprorelin

## Key facts

- **NCT ID:** NCT06627530
- **Lead sponsor:** Brazilian Clinical Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-02-17
- **Primary completion:** 2026-03
- **Final completion:** 2026-09
- **Target enrollment:** 144 (ESTIMATED)
- **Last updated:** 2026-02-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06627530

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06627530, "COACTION Trial - COmbination Androgen bloCkade in inTermediate to hIgh-risk prOstate caNcer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06627530. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*